Keryx Biopharmaceuticals Inc (KERX) SEC Filing 8-K Material Event for the period ending Wednesday, October 24, 2018

Keryx Biopharmaceuticals Inc

CIK: 1114220 Ticker: KERX

View differences made from one to another to evaluate Keryx Biopharmaceuticals Inc's financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 8-K Corporate News to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Keryx Biopharmaceuticals Inc.


Assess how Keryx Biopharmaceuticals Inc's management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Keryx Biopharmaceuticals Inc's Definitive Proxy Statement (Form DEF 14A) filed after their 2018 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors


SEC Filing Tools
Ticker: KERX
CIK: 1114220
Form Type: 8-K Corporate News
Accession Number: 0001193125-18-307860
Submitted to the SEC: Thu Oct 25 2018 5:15:00 PM EST
Accepted by the SEC: Thu Oct 25 2018
Period: Wednesday, October 24, 2018
Industry: Pharmaceutical Preparations
  1. New Agreement
  2. Other Events

External Resources:
Stock Quote
Social Media

Bookmark the Permalink: